Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NateraMEX:NTRA 50 Cyclically Adjusted PS Ratio is 39.83 as of Sep. 08, 2026, which is 95% above its 10-year median of 20.46. GuruFocus rates MEX:NTRA with a GF Score™ of 50/100 and a GF Value™ of MXN3,093.55 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 135 Medical Diagnostics & Research companies, Natera ranks worse than 97.04% on this metric.
As of today (2026-09-08), Natera's current share price is MXN5500.00. Natera's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN138.10. Natera's Cyclically Adjusted PS Ratio for today is 39.83.
The historical rank and industry rank for Natera's Cyclically Adjusted PS Ratio or its related term are showing as below:
MEX:NTRA'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.12 Med: 20.46 Max: 34.59
Current: 34.18
During the past years, Natera's highest Cyclically Adjusted PS Ratio was 34.59. The lowest was 6.12. And the median was 20.46.
MEX:NTRA's Cyclically Adjusted PS Ratio is ranked worse than 97.04% of 135
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs MEX:NTRA: 34.18
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Natera's adjusted revenue per share data for the three months ended in Jun. 2026 was MXN91.672. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN138.10 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Natera (MEX:NTRA) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Natera Cyclically Adjusted PS Ratio Related Terms
Natera Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Natera's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NTRA vs IDXX, A, IQV: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Natera's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Natera's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Natera's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 39.83 mean?
Natera (MEX:NTRA) has a Cyclically Adjusted PS Ratio of 39.83 as of Sep. 08, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Natera and its competitors. This is 95% above median its historical median of 20.46. Over the past decade, Natera's Cyclically Adjusted PS Ratio has ranged from 6.12 to 34.59. According to the industry distribution chart, Natera ranks #131 out of 135 companies in the Medical Diagnostics & Research industry, placing it in the top 97%.
Is Natera's Cyclically Adjusted PS Ratio too high?
Natera's current Cyclically Adjusted PS Ratio of 39.83 is 95% above median its 10-year median of 20.46. Over the past 10 years, this metric has ranged from a low of 6.12 to a high of 34.59. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 2.06. Natera's value of 39.83 is 1833.5% above this industry median. Based on the distribution chart, Natera ranks #131 out of 135 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Natera has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Cyclically Adjusted PS Ratio compare to IDXX and A?
According to the Medical Diagnostics & Research industry distribution chart, Natera ranks #131 out of 135 companies for Cyclically Adjusted PS Ratio. This places Natera in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.06. Natera's value of 39.83 is 1833.5% above this benchmark. Historically, Natera's own Cyclically Adjusted PS Ratio has ranged from 6.12 to 34.59 over the past decade. While the company's 10-year median is 20.46 vs. the industry median of 2.06, Natera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 2.06, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natera's current Cyclically Adjusted PS Ratio of 39.83 is 1833.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Natera and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natera's current Cyclically Adjusted PS Ratio is 39.83, which is 95% above median its own 10-year median of 20.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (MEX:NTRA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN3,093.55, compared to a current price of MXN5,500.00 — trading 77.8% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 39.83, which is 95% above median its 10-year median of 20.46 and 1833.5% above the Medical Diagnostics & Research industry median of 2.06. Natera's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Natera (MEX:NTRA), the current Cyclically Adjusted PS Ratio is 39.83 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natera (MEX:NTRA) Overvalued in 2026?
Based on GuruFocus' analysis, Natera stock appears to be overvalued.
The current stock price of MXN5,500.00 is trading 77.8% above its estimated GF Value™ of MXN3,093.55.
GuruFocus considers Natera to be Significantly Overvalued.
Key valuation signals for MEX:NTRA:
Cyclically Adjusted PS Ratio: 39.83 (95% above median its 10-year median of 20.46)
GF Value™: MXN3,093.55 vs. price of MXN5,500.00 (77.8% above fair value)
Industry Position: 1833.5% above the Medical Diagnostics & Research median (#131 of 135)
No single metric tells the full story. See the MEX:NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
50GF Score
Get the complete analysis for MEX:NTRA
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NTRA has been successfully added to your 
